Research Article
BibTex RIS Cite

Year 2023, , 69 - 72, 31.12.2023

Burak Oğulcan Yıldırım

https://doi.org/10.7197/cmj.1410528

Abstract

References

  • 1-Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34(3):307-10.
  • 2-Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm. 2014;2014:232167. doi: 10.1155/2014/232167. Epub 2014 May 6.
  • 3- Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012 Jul;36(1):39-45.
  • 4- Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath. 2014 Jul 24. (Epub ahead of print).
  • 5- Zhou S, Nao J. Nesfatin-1: A biomarker and potential therapeutic target in neurological disorders. Neurochem Res. 2023. https://doi.org/10.1007/s11064-023-04037-0.
  • 6. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443: 709-12.
  • 7. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31: 543-7.
  • 8. Kim J, Yang H. Nesfatin-1 as a new potent regulator in reproductive system. Dev Reprod 2012; 16: 253-64. 9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006; 6(10): 772–78.
  • 10. Conde J, Scotece M, G´omez R.et al. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37( 6):413–420.
  • 11. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie. 2012; 94(10):2180–2189. 12. Sood A. Obesity, adipokines, and lung disease. Journal of Applied Physiology. 2010;108(3):744–753.
  • 13. Scotece M, Conde J, Vuolteenaho K, et al. Adipokines as drug targets in joint and bone disease. Drug Discovery Today. 2014;19(3): 241–258.
  • 14. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y, A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun. 2012;418:676–681.
  • 15. Çatlı G, Anık A, Küme T, Çalan ÖG, Dündar BN, Böber E, et al. Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J Endocrinol Invest. 2015; 38: 909-13.
  • 16. Park MG, Ko KW, Oh MM, Bae JH, Kim JJ, Moon du G. Effects of smoking on plasma testosterone level and erectile function in rats. J Sex Med. 2012; 9: 472-81.
  • 17. Ayada C, Toru Ü, Korkut Y . Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19 (1): 4-10. 7s.
  • 18. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013; 14: 189-195.
  • 19. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depotspecific adipokine with increased levels in obesity. Endocrinology. 2010; 151: 3169-80.

EVALUATION OF THE EFFECT OF SMOKING ON NESFATIN-1 LEVEL

Year 2023, , 69 - 72, 31.12.2023

Burak Oğulcan Yıldırım

https://doi.org/10.7197/cmj.1410528

Abstract

Aim: Nesfatin-1 is a recently discovered adipocytokine that is believed to regulate food intake and is linked to body mass index. While its precise mechanism of action remains unclear, a deeper understanding of how nesfatin-1 interacts with metabolic diseases, inflammation, and insulin resistance could have significant implications for the treatment of a wide range of conditions, including cardiovascular disease.
Smoking is a complex issue with roots in social, cultural, and economic factors that can contribute to nicotine addiction. Additionally, nicotine's ability to stimulate the mind and promote feelings of relaxation can create a positive feedback loop that makes it difficult to quit. Unfortunately, there is limited research on the effects of smoking on Nesfatin-1 levels. However, one study found that women who smoke tend to have lower levels of Nesfatin-1. To build on this finding, the present study aims to further investigate nesfatin-1 levels in both smokers and non-smokers.
Methods: A total of 70 participants, smokers (n=35) and non-smokers (n=35), were included in the study. The participant's gender, age, height and weight, body mass index, and nesfatin-1 levels were measured and compared.

The SPSS 23.0 program was used to evaluate the data statistically. Data were evaluated with a t-test. The error level was taken as 0.05.

Result: Serum Nesfatin-1 levels were significantly higher in smokers (13.73± 3.11) than in non-smokers (8.63 ± 0.91) (t=-9.315, p<0.01). No significant difference was found between other parameters in the smoker and non-smoker groups.

Conclusion: Our study has shown that individuals who smoke display higher levels of Nesfatin-1 compared to non-smokers, indicating a correlation between smoking and Nesfatin-1. However, further investigation is required to understand the mechanism behind this increase. It is hoped that continued research will unveil the potential of Nesfatin-1 in treating human obesity.

Keywords

Smoking Nesfatin Nutrition

Ethical Statement

Prior to conducting the research, appropriate permissions and ethical clearance were secured from the (No. 2019-03/02) was obtained from the Sivas Cumhuriyet University Faculty of Medicine Ethics Committee. In this manner, individuals provided informed consent before their participation.

References

  • 1-Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34(3):307-10.
  • 2-Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm. 2014;2014:232167. doi: 10.1155/2014/232167. Epub 2014 May 6.
  • 3- Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012 Jul;36(1):39-45.
  • 4- Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath. 2014 Jul 24. (Epub ahead of print).
  • 5- Zhou S, Nao J. Nesfatin-1: A biomarker and potential therapeutic target in neurological disorders. Neurochem Res. 2023. https://doi.org/10.1007/s11064-023-04037-0.
  • 6. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443: 709-12.
  • 7. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31: 543-7.
  • 8. Kim J, Yang H. Nesfatin-1 as a new potent regulator in reproductive system. Dev Reprod 2012; 16: 253-64. 9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006; 6(10): 772–78.
  • 10. Conde J, Scotece M, G´omez R.et al. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37( 6):413–420.
  • 11. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie. 2012; 94(10):2180–2189. 12. Sood A. Obesity, adipokines, and lung disease. Journal of Applied Physiology. 2010;108(3):744–753.
  • 13. Scotece M, Conde J, Vuolteenaho K, et al. Adipokines as drug targets in joint and bone disease. Drug Discovery Today. 2014;19(3): 241–258.
  • 14. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y, A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun. 2012;418:676–681.
  • 15. Çatlı G, Anık A, Küme T, Çalan ÖG, Dündar BN, Böber E, et al. Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J Endocrinol Invest. 2015; 38: 909-13.
  • 16. Park MG, Ko KW, Oh MM, Bae JH, Kim JJ, Moon du G. Effects of smoking on plasma testosterone level and erectile function in rats. J Sex Med. 2012; 9: 472-81.
  • 17. Ayada C, Toru Ü, Korkut Y . Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19 (1): 4-10. 7s.
  • 18. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013; 14: 189-195.
  • 19. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depotspecific adipokine with increased levels in obesity. Endocrinology. 2010; 151: 3169-80.
There are 17 citations in total.

Details

Primary Language English
Subjects Health Services and Systems (Other)
Journal Section Medical Science Research Articles
Authors

Burak Oğulcan Yıldırım 0000-0003-3448-6187

Publication Date December 31, 2023
Submission Date December 27, 2023
Acceptance Date December 28, 2023
Published in Issue Year 2023

Cite

AMA Yıldırım BO. EVALUATION OF THE EFFECT OF SMOKING ON NESFATIN-1 LEVEL. CMJ. December 2023;45(4):69-72. doi:10.7197/cmj.1410528